Tylovet

Quick links to important sections

Tylovet

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tylovet

Quick Facts

Property Description
Active ingredient Tylosin (commonly as Tylosin tartrate)
Primary Form Injection solution, Water-soluble powder
Pharmacological class Macrolide Antibiotic, Antimicrobial Agent
Common Use Domain Veterinary Medicine (Livestock and Poultry)
Origin Semi-synthetic derivative

What Type of Medicine is Tylovet?

Tylovet is the designation for a specialized veterinary pharmaceutical whose core active substance is Tylosin, a compound classified specifically as a macrolide antibiotic. This product is a single-ingredient formulation reserved for use in animal health, targeting susceptible bacterial infections in animals such as livestock and poultry.

The active ingredient, Tylosin, is a semi-synthetic derivative that is naturally produced by the bacterium Streptomyces fradiae. This specialized nature places it within a niche group of antimicrobials designed for large-scale application in production animals, a factor in its use for maintaining herd health.

Tylosin: Core Composition and General Purpose

The general purpose of Tylovet is to function as a systemic antimicrobial agent to help control and suppress the proliferation of susceptible bacteria. The action of Tylosin is primarily bacteriostatic, meaning it inhibits bacterial growth rather than directly destroying the microbes. Tylosin achieves this by binding to the 50S ribosomal subunit, thereby inhibiting the bacteria's ability to create essential proteins required for reproduction. This specific action prevents the microbial population from increasing, giving the treated animal's immune system the opportunity to resolve the infection.

Available Forms and Application Context

Tylovet is supplied in two principal dosage forms to accommodate various administration contexts: an injection solution and a water-soluble powder. The liquid solution is primarily intended for parenteral delivery, such as intramuscular injection, providing direct access to the systemic circulation. Conversely, the water-soluble powder is designed for oral administration by being dissolved in drinking water, which is a common method for treating large groups of animals. These distinct pharmaceutical preparations are designed to offer veterinary professionals flexibility based on the scale of the therapeutic need.

Regulatory References

  1. FDA Tylosin Information

What side effects are possible with Tylovet?

Possible Side Effects and Safety Information

The safety profile of Tylovet (Tylosin) is officially defined by specific adverse reactions, system-organ classes involved, and absolute restrictions on use, as detailed in governmental regulatory documents. The most commonly reported side effects fall under Gastrointestinal Disorders and Skin and Subcutaneous Tissue Disorders.


Official Adverse Reaction Scope

The frequency of many adverse reactions in target species, such as swine, is often classified as undetermined as it cannot be reliably estimated from available data. However, reactions in swine, including diarrhoea, rectal oedema, and rectal prolapse, are explicitly noted as transient, typically appearing 48–72 hours after the start of treatment.

System-Organ Class Key Adverse Reactions Listed
Gastrointestinal Disorders Diarrhoea, decreased appetite, rectal oedema, rectal prolapse
Skin and Subcutaneous Tissue Disorders Pruritus (itching), reddening of the skin
General & Administration Site Pain and inflammation at the injection site

Critical Safety Restrictions and Serious Reactions

The regulatory label places absolute contraindications on the use of Tylosin in specific animal populations. Tylosin is strictly contraindicated in horses and ponies due to the serious, documented risk of inducing severe, potentially fatal diarrhoea. The medication is also contraindicated in animals with known hepatic disorders (liver disease) or those with hypersensitivity to Tylosin or other drugs in the macrolide class. Official labeling notes the potential for antagonism with lincosamide and aminoglycoside antibiotics, which may affect its activity.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents for Tylovet (Tylosin) describe specific scenarios and severe manifestations associated with overexposure that necessitate emergency action.

Officially Documented Overdose Outcomes

The most critical regulatory warning is against the administration of Tylosin injection to horses or other equine species, as this practice has been documented to result in a fatal outcome. Beyond this species-specific risk, severe systemic events have been reported in regulatory studies, including signs of shock, convulsions, and death. Other overdose presentations observed in high-dose scenarios include depression, prostration, vomiting, salivation, and defecation, affecting the central nervous and gastrointestinal systems. Conversely, regulatory safety studies indicate that certain populations, such as growing pigs, display no signs of intolerance at doses significantly exceeding the recommended level.

Emergency Actions and Management

In the event of accidental human ingestion, official emergency guidance requires individuals to seek medical advice immediately and to present the product labeling to the physician. When an overdosage is confirmed or highly suspected, immediate professional intervention is necessary due to the potential for life-threatening consequences. Management of an overdosage relies solely on symptomatic and supportive treatment, as the regulatory information does not list or define a specific antidote for Tylosin.

Therapeutic Uses of Tylovet

What Tylovet Treats: Main Uses and Benefits

Tylovet is relevant for managing bacterial and Mycoplasma infections in livestock and poultry, applied across domains where additional symptomatic support is needed. This medication is commonly used to help with multiple symptomatic domains and is applied across clinical settings that involve acute or disruptive symptom patterns.

The medication is commonly used to help manage conditions such as Chronic Respiratory Disease (CRD) and infectious sinusitis in poultry, Swine Dysentery and infectious arthritis in pigs, acute mastitis, metritis, and is considered relevant for managing conditions that may lead to complications like liver abscesses in cattle. This use supports the animal during difficult episodes by easing distress and contributes to easing the overall symptom load.

“It is applied in addressing symptom clusters that include pronounced digestive upset, severe coughing, and symptoms related to physical discomfort.”

The support provided by this medication is relevant for managing symptoms related to physical discomfort, like lameness or labored breathing, and is relevant when supportive symptom management is appropriate in contexts involving heightened systemic burden.


Quick Fact: Relief for Respiratory and Systemic Strain

Domain Key Symptoms Managed Benefit Provided
Respiratory/Enteric Coughing, bloody scours, labored breathing Supports general well-being during symptomatic phases
Inflammatory/Local Lameness, inflammation, pain during acute episodes Contributes to easing the overall symptom load

Regulatory References

  1. National Institutes of Health (NIH) DailyMed

Eligibility and Restrictions for Use

The eligibility profile for the veterinary medicine Tylovet (Tylosin) is strictly defined by regulatory documents focusing on species safety and food production status.

Populations Who Can and Cannot Use Tylovet

Use of Tylovet is officially established and permitted in Swine, Beef and Nonlactating Dairy Cattle, Chickens, Turkeys, and Honey Bees.

Eligibility Status Animal Population Regulatory Restriction Basis
Contraindicated Horses or Equine Species Prohibited due to the risk of severe, potentially fatal adverse effects.
Contraindicated Lactating Dairy Cattle Prohibited due to food safety regulations regarding drug residue in milk.
Contraindicated Laying Hens Prohibited if producing eggs for human consumption due to food safety regulations.
Contraindicated Hypersensitive Animals Must not be used in animals with a known allergy to Tylosin or other macrolide antibiotics.
Restricted Use Pre-ruminating Calves Use is not established for calves intended for veal, and a withdrawal period is undefined.

Condition-specific limitations also prohibit the use of Tylovet in animals diagnosed with hepatic disorders (liver disease). For pregnant animals, safety has often not been fully established, and use is permitted only following a careful benefit/risk assessment by the veterinarian. The 200 mg/mL injectable solution is also not recommended for use in pigs weighing less than 25 pounds.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Tylovet (Tylosin) based on its activity as a macrolide antibiotic and its potential to inhibit hepatic enzymes. Co-administration with certain substances is subject to specific warnings and restrictions.

Documented Drug-Drug Interactions

Interaction Type Interacting Substances Official Description
Pharmacodynamic Antagonism Lincosamide antibiotics (e.g., Lincomycin), Chloramphenicol Co-administration may reduce antimicrobial efficacy due to competition at the bacterial 50S ribosomal subunit.
Exposure Modification Digitalis glycosides (e.g., Digoxin), Xanthine derivatives Tylosin's hepatic enzyme inhibition may decrease the metabolism and clearance of these drugs, potentially increasing their plasma concentrations and risk of toxicity.
Cross-Resistance Risk Macrolides, Lincosamides, Streptogramin B Tylosin use may induce bacterial cross-resistance, reducing the effectiveness of related antimicrobial classes.

Regulatory Restrictions and Warnings

Restriction Category Constraint Context
Administration Restriction The injection solution must not be physically mixed with other injectable solutions. Prohibited due to the risk of active ingredient precipitation and physical-chemical incompatibility.
Population/Species Contraindication Tylosin use is a formal contraindication in horses and other equine species. Restriction based on the risk of severe, sometimes fatal gastrointestinal adverse reactions in these animals.

No formal drug-food, alcohol, or herbal product interactions are documented in the official regulatory information for Tylovet.

Mechanism of Action

Selective Inhibition of Bacterial Protein Synthesis

The action of Tylovet is solely determined by the pharmacodynamic mechanism of its active ingredient, Tylosin, which targets the essential machinery for bacterial survival and replication. This mechanism is defined by the reversible binding of Tylosin to the 50S ribosomal subunit found only in susceptible bacteria. Tylosin acts as an inhibitor by physically embedding itself within the 23 S ribosomal RNA, effectively blocking the nascent peptide exit tunnel. This molecular interference halts the elongation phase of protein synthesis.


Functional Arrest of Microbial Proliferation

The immediate consequence of blocking protein synthesis is the bacteriostatic effect, meaning the mechanism stops the growth and replication of the bacterial population. This functional arrest of microbial proliferation stabilizes the pathogenic load. The resulting reduction in proliferation enables host defenses to act on the stationary microbial population.


Constraints of Mechanistic Selectivity

The mechanism is selectively active due to the unique structure of the bacterial 70 S ribosome compared to the host's 80 S ribosomes. However, the action is constrained by acquired resistance mechanisms, notably the methylation of the 23 S ribosomal RNA binding site, which prevents Tylosin from docking. Additionally, the presence of bacterial efflux pumps actively transports the molecule out of the cell, functionally reducing the resulting inhibitory concentration.

Dosage and Administration Information

Tylovet (Tylosin) administration includes oral routes (medicated feed or water), topical dusting, or intramuscular injection, depending on the specific animal and product formulation. The most common usage patterns involve the oral administration of the water-soluble powder dissolved in drinking water or the medicated feed premix mixed into the complete ration.

Administration is based on specific dose concentrations and duration protocols. For poultry and swine, dosing is defined by the concentration of Tylosin per gallon of water (e.g., 2,000 mg/gallon for certain poultry uses), to ensure a specified milligrams per pound of body weight is achieved. In beef cattle, the dosage is calculated to deliver 60 to 90 mg of Tylosin per head per day through the medicated feed, with feed concentration adjusted to meet this intake rate.

Scheduling patterns range from short-term courses lasting 1 to 10 days for initial water-based treatments, to continuous use when administered as a medicated feed premix. During any water or feed medication period, the medicated ration or water is maintained as the sole source available to the animals. Furthermore, the water solution is prepared fresh every three days, with the powder added to the water to ensure correct dissolution and stability.

Recent Clinical Evidence

Research evidence / Overview of studies for Tylovet

Evidence Base for Respiratory Illnesses in Poultry

Research examining Tylosin administration for respiratory conditions, specifically Chronic Respiratory Disease (CRD) and related infections in poultry, was conducted primarily through Controlled Field Trials and laboratory-based studies. It focused on populations such as broiler chickens, laying hens, and turkeys that were affected by Mycoplasma species.

The studies were designed to evaluate outcomes related to physical discomfort, mainly by scoring respiratory symptoms like coughing and labored breathing, during the typically short treatment period. These studies also included data collection on mortality rates. Findings indicate patterns regarding the evolution of these respiratory signs in the observed populations.

Evidence Base for Digestive and Enteric Conditions in Swine

For digestive conditions in pigs, such as Swine Dysentery and Porcine Proliferative Enteropathy (Ileitis), the evidence is built on Controlled Clinical Trials and reviews of regulatory dossiers. Research explored the use of Tylosin administration in swine populations that were either naturally or experimentally infected with the causative bacteria.

These trials explored outcomes related to systemic or functional imbalance, such as the measurement of diarrhea incidence and severity and changes in fecal consistency. For Ileitis, studies also monitored physical outcomes, including the assessment of gross intestinal lesion scores observed in the populations. Findings indicate patterns regarding the incidence and severity of digestive issues in the groups studied.

Research Findings for Tylosin-Responsive Diarrhea in Other Populations

A distinct line of research explored Tylosin administration in Randomized, Placebo-Controlled, Double-Blinded, Prospective Clinical Trials (RCTs) to evaluate its role in Tylosin-Responsive Diarrhea (TRD). This condition is characterized by fluctuating or episodic manifestations of chronic diarrhea in dogs where other causes have been ruled out. These studies monitored changes in fecal consistency scores and the time interval until recurrence was observed after the treatment was stopped.

Duration of Evidence and Key Limitations

The available research provides context primarily for short-term symptom changes related to the active treatment period, typically spanning between three and fourteen days. Long-term effects are not fully established across the research landscape. Follow-up durations were often limited, meaning research provides only short-term insight into symptom changes.

The overall evidence supporting the regulatory status of Tylosin is categorized in scientific reports as High to Moderate across the primary indications. Key limitations noted in scientific reviews include the potential for antimicrobial resistance among target pathogens, and the fact that the results apply only to the specific populations studied.

Key Studies & References

  1. The efficacy of tylosin and tilmicosin against experimental Mycoplasma gallisepticum infection in chickens
  2. FREEDOM OF INFORMATION SUMMARY - ANADA 200-484 TYLOVET 100 (tylosin phosphate) Type A medicated article (FDA Regulatory Document)
  3. Tylosin (TYL) - Medicating Ingredient Brochure (Canadian Food Inspection Agency/CFIA)

Frequently Asked Questions (FAQ)

Common questions about Tylovet (FAQ)


Q: How long does it usually take to feel a difference after starting Tylovet?

Regulatory-aligned documents note that for specific uses, initial signs of improvement may begin to be observed within one to two days after starting administration. However, this time frame can vary depending on the condition being addressed and the species receiving the medicine.

Q: Can Tylovet be taken on an empty stomach?

Official information for some formulations indicates that the medicine can be administered with or without food. Providing the medicine with food may be mentioned in official-aligned guidance as a measure that may aid in reducing the possibility of stomach upset.

Q: What are the restrictions on food or drinks when taking Tylovet?

Official regulatory instructions for oral administration, such as in medicated feed or drinking water, mandate a key restriction: the medicated ration or water must be the sole source of feed or water available to the animals during the treatment period.

Q: Can Tylovet affect the results of lab tests?

Some macrolide antibiotics, including the active ingredient in Tylovet, may be described in regulatory-associated materials as potentially causing a false elevation in the results of certain liver function blood tests, such as ALT and AST.

Q: Is it common to have an allergic reaction to Tylovet?

Hypersensitivity (allergy) to the active ingredient or other related macrolide antibiotics is listed in official documents as a reason not to use the product (a contraindication). If severe signs like a rash, fever, or trouble breathing are observed, official safety materials note that prompt consultation with a professional is necessary.

Q: Are the common side effects of Tylovet long-lasting?

For many of the commonly noted adverse reactions, such as diarrhea and rectal swelling in swine, official labeling describes these reactions as being transient. This means they are temporary and are expected to resolve on their own.

Q: What are the most serious possible side effects of Tylovet?

The most critical safety risk noted in official documents is the potential for severe, sometimes fatal diarrhea in horses, which is why the drug is formally contraindicated in that species. In approved species, severe reactions that may occur include rectal prolapse and pain or inflammation at the injection site.

Q: Can you take Tylovet if you have a history of liver issues?

Official regulatory documents place a contraindication on the use of Tylovet in animals diagnosed with pre-existing hepatic disorders (liver disease). Official documentation states that the product is contraindicated for use in this circumstance.

Q: Is there a specific time of day that is best for taking Tylovet?

While official administration protocols do not specify a particular time of day, guidance associated with the medicine often suggests administering the medicine at the same time each day. This practice is intended to help achieve and maintain consistent drug levels.

Q: What happens if a dose of Tylovet is missed?

Official-aligned guidelines generally suggest that if a dose is missed, it should be given as soon as possible. However, if it is already near the time for the next scheduled dose, the product information states that the missed dose should be omitted to avoid the risk of administering a double dose.

Q: Is Tylovet suitable for older adults?

Official documents do not list advanced age in geriatric or older animal populations as a specific contraindication for approved species. Restrictions mainly apply to young animals, such as pre-ruminating calves and pigs weighing less than 25 pounds.

Q: What is the general safety profile of Tylovet?

The official safety profile is defined by absolute contraindications in certain species (like horses) and conditions (like liver disease). Safety information also notes specific adverse reactions, primarily involving the gastrointestinal tract (like diarrhea) and skin.

Q: How long do most people take Tylovet for?

Official administration schedules for Tylovet range widely. They include short-term courses lasting 1 to 10 days for initial water-based treatments, as well as longer, continuous use when the product is administered as a medicated feed premix.

Q: Can Tylovet be crushed or split?

Official forms are supplied as an injection solution or water-soluble powder. Although guidance exists for compounding pharmacies to place the powder into capsules to help administration, official documents do not provide instruction for crushing or splitting solid dosage forms.

Q: What are the official sources of information about Tylovet?

Authoritative information can be found in official regulatory resources published by government agencies. These include the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH) DailyMed, and the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

Q: Is Tylovet a drug that is easy to stop using suddenly?

Official guidance emphasizes the importance of continuing the full course of treatment as prescribed by a professional. Stopping or skipping doses may reduce the effectiveness of the treatment, and official guidance does not typically recommend this practice.

Q: What distinguishes Tylovet's mechanism from other drugs in the same class?

Tylovet's active ingredient, Tylosin, is a macrolide antibiotic. Its mechanism is defined by its ability to inhibit bacterial protein synthesis by reversibly binding to the 50S ribosomal subunit in susceptible bacteria.

Q: What is the shelf life of Tylovet?

The shelf life depends on the specific product form. For the injection solution, the shelf life is often three years from the date of manufacture. For some liquid feed preparations, the regulatory expiration date may be defined as 31 days after the date of manufacture.

Q: Do you need regular check-ups while taking Tylovet?

Official monitoring requirements are often not explicitly detailed on the product label. However, some professional guidance suggests that a professional may monitor the animal to assess if the medication is working as expected and to observe for any adverse reactions.

Q: How is Tylovet classified by regulatory bodies?

Tylovet is officially classified by regulatory bodies as a macrolide antibiotic for veterinary use. It is often regulated as a Prescription Only Medicine (POM-V) in jurisdictions like the UK and has specific codes (like ATCvet QJ01FA90) for classification.

Q: What should I do if I notice an unusual change while on Tylovet?

Regulatory guidance and associated safety information indicate that if signs of an adverse reaction, such as a severe or unusual change, are observed, the product should be discontinued, and consultation with a professional is noted as essential.

How should Tylovet be stored and disposed of?

How to Store and Dispose of Tylovet

Official regulatory documents define strict storage and disposal requirements for Tylovet (tylosin) to ensure product stability and safety.


Storage Conditions

Tylovet must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Protection is required against moisture, light, and excessive heat; the product must not be frozen. The container must be kept tightly closed and stored out of the sight and reach of children (European labeling) or locked up (US labeling).

Stability is limited to the expiry date printed on the label and, for some forms, a short period (e.g., 24 hours) after reconstitution.


️ Disposal Instructions

Unused or expired product and its container must be disposed of according to local requirements, often requiring transfer to an approved waste disposal plant. Official instructions strictly forbid the contamination of water, food, or feed during storage or disposal, emphasizing that the medicine should not be discarded via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tylovet found in:

A-Z Index: